Antibodies against Claudin 18.2 useful in cancer diagnosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9512232
APP PUB NO 20150147763A1
SERIAL NO

14397244

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASTELLAS PHARMA INC5-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU TOKYO 1038411 ?1038411

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Mitnacht-Kraus, Rita Friedberg, DE 24 162
Sahin, Ugur Mainz, DE 331 2329
Türeci, Özlem Mainz, DE 76 516
Wöll, Stefan Nackenheim, DE 10 99

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 6, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00